Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
LipoScience IPO: Sale of 5 mil. shares in $80 mil. initial public offering is postponed Sept. 19. The maker of the NMR LipoProfile cardiovascular disease risk assessment test planned on pricing each share at $14-16 (1"The Gray Sheet" March 11, 2002, p. 18). The IPO, which originally had been targeted to raise $100 mil., was delayed following the stock market downturn the week of Sept. 16. The NMR LipoProfile is more expensive than traditional, standard-of-care cholesterol tests, which may have contributed to investor jitters...
You may also be interested in...
Boston Scientific Gains Neuro, Cardiovascular Access Devices Via Acquisition
Microfabricated guidewires to facilitate interventional cardiology procedures will be developed by Boston Scientific, following the purchase of Precision Vascular Systems, Inc
Boston Scientific Gains Neuro, Cardiovascular Access Devices Via Acquisition
Microfabricated guidewires to facilitate interventional cardiology procedures will be developed by Boston Scientific, following the purchase of Precision Vascular Systems, Inc
Centerpulse settles opt-outs
Swiss company reaches settlements Nov. 6 with 16 individuals who opted out of a $725 mil. hip-and-knee class action settlement and had revision surgery. The firm must still resolve suits with 43 non-revision patients. On Nov. 4, Centerpulse transferred $725 mil. to a settlement trust in Cleveland, completing its obligations to class participants. Funds were raised through a capital increase via a tradeable preemptive rights offering, in addition to bank credit (1"The Gray Sheet" Sept. 23, 2002, p. 17)...